Richmond Pharmacology is pleased to confirm our attendance at The Liver Meeting 2025,hosted by the American Association for the Study of Liver Diseases (AASLD),taking place in Washington, DC, from 7th –11th November.

 

Representing Richmond at The Liver Meeting:

·        James Rickard,Chief Scientific Officer

 

James looks forward to engaging with industry and academic partners to discuss Richmond’s expertise in:

·        Early-phase hepatology and metabolic liver disease trials

·        First-in-human and dose-ranging studies

·        Non-invasive biomarkers and digital health integration

·        Regulatory strategy and multi-regional trial delivery

·        Patient-focused approaches in complex liver studies

 

If you’re attending AASLD 2025 and seeking a clinical development partner in liver disease research, get in touch to arrange a meeting with James: info@richmondpharmacology.com

Learn more: The Liver Meeting | AASLD

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event